Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

Uric acid has been linked to the progression of native kidney disease.

Studies evaluating its contribution to allograft function in kidney transplant recipients, among whom hyperuricemia is common, have yielded mixed results.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

The researchers evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy (IF/TA) in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) Trial participants.

Subjects underwent uric acid, iothalamte GFR, and urine albumin to creatinine (ACR) measurements annually for 5 years in addition to an allograft biopsy at baseline and 5 years.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The timeline in the abstract includes 5 years.

What Was Measured

Studies evaluating its contribution to allograft function in kidney transplant recipients, among whom hyperuricemia is common, have yielded mixed results.

The subject headings attached to it are Allografts, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Atrophy, Biopsy, Chronic Disease and Creatinine.

What This Means in Plain Language

The paper is a randomized and double-blind study of Angiotensin II over 5 years.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Transplantation), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.